Cariprazine, a dopamine and serotonin receptor partial agonist, was effective in reducing depressive symptoms in adults with bipolar I depression, according to a phase 3 trial in the American Journal of Psychiatry. Few effective treatments are available for patients with bipolar depression, and those currently used can cause mania.
The 488 patients were randomly assigned to receive cariprazine at 1.5 mg per day, 3.0 mg per day, or to placebo for 6 weeks. Depressive symptoms were measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).
Slomski A. Cariprazine Benefits Patients With Bipolar Depression. JAMA. 2019;321(24):2396. doi:10.1001/jama.2019.8399
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: